Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Objectives • Understand relationship between mtDNA content and Female age Embryo ploidy Embryo viability • Consider the technical requirements for mtDNA measurement • Gain an insight into the current evidence for mtDNA as a biomarker of embryo viability Questions: • Do you think mtDNA might have value as a biomarker of embryo viability? A) Yes, quite likely B) No, highly unlikely C) Not sure • Do you think amount of mtDNA can be accurately measured? A) Yes, measurements should be straightforward B) Yes, but quantification is challenging C) mtDNA can not be accurately measured D) Not sure Background - Mitochondria • Involved in vital cellular processes: • The main cellular powerhouses • Cells contain from 100 to >150,000 • Each mitochondrion contains one or more copies of its own genome (mtDNA) • Little change in mtDNA content until first cellular differentiation May-Panloup et al., 2005 ; St John et al., 2010 Comprehensive Examination of mtDNA quantity chromosome screening (aCGH or NGS) Trophectoderm biopsy Whole genome amplification 2015 mtDNA quantification (real-time PCR or Next Generation Sequencing) Materials and methods • Embryo biopsy • Whole genome amplification • Quantitative PCR Amplification of several loci within the mtDNA Amplification of multi-copy nuclear DNA sequence (Alu) Normalise mtDNA against nuclear DNA • Next generation sequencing (not using a low pass PGS strategy) mtDNA reads counted nuclear DNA reads counted Normalise mtDNA against nuclear DNA mtDNA quantity with age mtDNA quantity changes with advancing age Cleavage stage: mtDNA quantity decreases with advancing female age (P= 0.01) Result representative of fertilised oocyte mtDNA Blastocyst stage: mtDNA quantity increases with advancing female age (P= 0.003) Result representative of embryonic mtDNA mtDNA quantity and aneuploidy mtDNA quantity is associated with embryo ploidy Elevated mtDNA quantity in aneuploid vs. euploid blastocysts (P= 0.025) Analysis of different blastocyst cohort via NGS Aneuploid blastocysts have higher mtDNA levels vs. euploid (P= 0.006) mtDNA quantity relationship with embryo ploidy is independent of female age mtDNA quantity age and aneuploidy mtDNA content of blastocyst stage embryos increases with age mtDNA content is typically higher when embryos are aneuploid Female age Blastocyst mtDNA and embryo viability Retrospective analysis 0,02 mtDNA quantity 92 euploid blastocysts 0,015 28% of euploid blastocysts that failed to implant had elevated mtDNA Known outcome 0,01 Normal mtDNA levels 0,005 Elevated mtDNA levels 0 Pregnant Not-pregnant Fragouli et al., 2015 PLoS Genetics Conclusion - Biology Association between mtDNA quantity, age and aneuploidy risk Implies mitochondrial factor female reproductive aging/aneuploidy? Elevated mtDNA quantities arise after trophectoderm differentiation Elevated mtDNA quantities characteristic of embryos under stress ? Findings consistent with the “quiet embryo” hypothesis ? Controversy number 1 Several groups have reported confirmatory results (e.g. Fragouli et al., 2015; Diez-Juan et al., 2015; Spinella et al 2016) But some have failed to detect a link between mtDNA and viability (e.g. Victor et al., 2016; Treff et al., 2016) mtDNA must be normalised against nuclear DNA sequences to control for differences in the number of cells biopsied 5 cell biopsy specimen 2 2 2 2 2 5 cells = 10 copies of each nuclear gene (autosomal) Each cell has 5 mitochondria = 25 copies of the mtDNA Ratio of mtDNA to nuclear is 25:10 = 2.5 mtDNA must be normalised against nuclear DNA sequences to control for differences in the number of cells biopsied 3 cell biopsy specimen 2 2 2 3 cells = 6 copies of each nuclear gene (autosomal) Each cell has 5 mitochondria = 15 copies of the mtDNA Ratio of mtDNA to nuclear is 15:6 = 2.5 (i.e. same testing 5 cells) Normalisation against a single copy DNA sequence risks error 5 cell biopsy specimen 2 Allele dropout affects ~10% of cells 2 1 2 2 Approximately half of all 5-cell samples will experience this error. More than one-third will see ADO in two cells increasing apparent mtDNA levels by 25% 5 cells = 9 copies of each nuclear gene (autosomal) detected Each cell has 5 mitochondria = 25 copies of the mtDNA Ratio of mtDNA to nuclear is 25:9 = 2.8 Measurement of mtDNA - normalization vs. single copy gene Samples tested twice – normalization vs. 2 different single copy genes Are the results for the two genes identical as one would hope? 1,05 1 0,95 0,9 0,85 0,8 No. 0,75 0,7 0,75 0,8 0,85 0,9 0,95 This indicates that results are subject to extreme variability Single copy genes should not be used for normalization 1 Measurement of mtDNA after normalization using a Alu or multiple individual genes Test the same samples twice, once vs. Alu and once with multiple individual genes averaged together Are the results identical as one would hope? 2 1 0 4 6 8 10 -1 -2 -3 -4 Yes, very close to identical. -5 -6 Indicates that accurate quantification from TE biopsy requires normalization against multi-copy sequences or multiple distinct genes 12 Controversy number 2 Are we just seeing the effect of morphology Higher quality trophectoderm has smaller cells, therefore fewer mitochondria and lower quantities of mtDNA Extensive comparison of morphology and mtDNA quantity Morphology only has a small influence on mtDNA levels TE TE HighPoor quality Few cells Many cells 15 mitochondria / 3 4 nuclei 5 = =3.75 Conclusion - Technical It is essential to normalize mtDNA against nuclear DNA However, the nuclear DNA sequence must not be a single copy Morphology has only a small effect on mtDNA levels Most NGS methods used for PGS do not sequence the mtDNA adequately to allow reliable quantification MitoGrade Study update 1 Prospective clinical evaluation 1,505 embryos tested from 35 clinics 139 (9%) had elevated mtDNA We have known outcomes for 283 of the embryos: 65.0% led to an ongoing pregnancy and all had ‘normal’ mtDNA 35% failed to implant and one-third of these had elevated mtDNA Implantation rate for embryos with elevated mtDNA 0% (0/33) Implantation rate for embryos with normal mtDNA was 73.6% P<0.0001 MitoGrade Study update 2 Prospective, blinded, non-selection study (NYU) 200 embryos with MitoGrade and known implantation outcome Frequency of embryos with elevated mtDNA: 4.5% Implantation rates Entire cohort: 143/200 = 71.5% Embryos with elevated mtDNA: 0/9 = 0% Embryos with mtDNA in the normal range: 143/191 = 75% Percentage of non-implanting embryos with elevated mtDNA: 16% MitoGrade Study update 2 Proportion of embryos with elevated mtDNA is small at this clinic Nonetheless the difference in the implantation rate (normal mtDNA- versus elevated mtDNA) is highly significant (P<0.0001) Ongoing pregnancy rates Entire cohort: 143/200 = 61% Embryos with elevated mtDNA: 0% Difference in the ongoing pregnancy rate is significant (P=0.0002) Conclusion - Clinical What’s relevant for your clinical practice? Elevated mtDNA quantities characteristic of embryos under stress ? Potentially valuable for laboratory/media/process optimization? Embryos with elevated mtDNA extremely rare/absent in some clinics Threshold of mtDNA content established, above which implantation of a euploid blastocyst rarely/never occurs What’s relevant for your clinical practice? Example: patient 35 year old, blastocyst transfer Euploid implanting (40%) PGS selection: 62% implantation Euploid not implanting - Unknown reason (25%) Aneuploid (35%) no PGS selection: 40% implantation What’s relevant for your clinical practice? Example: patient 35 year old, blastocyst transfer Euploid implanting (40%) Euploid not implanting - Unknown reason Euploid not implanting - Elevated mtDNA Aneuploid (35%) PGS + MitoGrade selection: 70% implantation (estimated) Take-home message • Some controversy • When assessing mtDNA quantities, it is essential that accurate methods are used • Mounting evidence that mtDNA levels are associated with embryo viability • Randomized trials needed to define the clinical value Questions: • Do you think mtDNA might have value as a biomarker of embryo viability? A) Yes, quite likely B) No, highly unlikley C) Not sure • Do you think amount of mtDNA can be accurately measured? A) Yes, measurements should be straightforward B) Yes, but quantification is challenging C) mtDNA can not be accurately measured D) Not sure